100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Trump Says Anthropic No Longer Seen as National Security Threat 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical data for its lead immuno-oncology therapeutic candidate, CB-1158 has been selected for an oral presentation at the 2016 Keystone Symposia on Cancer Immunotherapy taking place January 24-28, 2016, in Vancouver, Canada. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a key immunosuppressive enzyme that limits T-cell proliferation in a wide range of tumors. Details for the presentation are as follows:
Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells
Date: January 27, 2016
Session: Novel Immunotherapeutic Approaches and Antibody Therapies
Time: 5:00 p.m. -7:00 p.m. PT
Presenter: Susanne Steggerda, Ph.D., Calithera Biosciences
Abstract #3014
Poster Display: 7:30 a.m. - 10:00 a.m. PT
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT:
Jennifer McNealey
650-870-1071
